19.69

10.12% 1.81

Novocure Ltd (NVCR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NVCR Giù? Forum Previsione

Precedente Chiudi:

$17.88

Aprire:

$18.29

Volume 24 ore:

1.07M

Relative Volume:

1.05

Capitalizzazione di mercato:

$1.93B

Reddito:

$577.74M

Utile/perdita netta:

$-149.78M

Rapporto P/E:

-10.59

EPS:

-1.86

Flusso di cassa netto:

$-78.21M

1 W Prestazione:

+16.79%

1M Prestazione:

+17.62%

6M Prestazione:

-14.95%

1 anno Prestazione:

+65.32%

Intervallo 1D:

$18.00

$19.77

Intervallo di 1 settimana:

$16.30

$19.77

Portata 52W:

$11.29

$24.73

Novocure Ltd Stock (NVCR) Company Profile

Nome

Novocure Ltd

Settore

Healthcare (1200)

Industria

Medical Devices (153)

Telefono

44 (0)15 3475 6700

Indirizzo

NO. 4 THE FORUM, ST. HELIER

Dipendente

1,453

Cinguettio

@novocure

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

NVCR's Discussions on Twitter

Confronta NVCR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NVCR Novocure Ltd	19.69	1.93B	577.74M	-149.78M	-78.21M	-1.86
ABT Abbott Laboratories	118.95	208.18B	41.22B	5.77B	6.49B	2.94
SYK Stryker Corp	388.14	148.70B	21.97B	3.59B	3.21B	6.74
BSX Boston Scientific Corp	90.75	133.32B	15.91B	1.79B	1.89B	0.82
MDT Medtronic Plc	86.27	111.27B	33.00B	4.29B	5.50B	2.71
EW Edwards Lifesciences Corp	72.07	42.66B	6.60B	4.16B	490.10M	2.34

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-16	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-28	Downgrade	H.C. Wainwright	Buy → Neutral
2023-08-08	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-08-04	Iniziato	SVB Securities	Outperform
2023-07-31	Aggiornamento	Evercore ISI	Underperform → In-line
2023-06-07	Aggiornamento	Wedbush	Underperform → Neutral
2023-05-16	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2023-01-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-01-05	Reiterato	H.C. Wainwright	Buy
2022-11-29	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-24	Downgrade	Piper Sandler	Overweight → Neutral
2022-07-05	Downgrade	Evercore ISI	In-line → Underperform
2022-05-16	Iniziato	H.C. Wainwright	Buy
2022-02-08	Iniziato	Loop Capital	Buy
2022-02-02	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-20	Aggiornamento	Truist	Hold → Buy
2022-01-03	Aggiornamento	Evercore ISI	Underperform → In-line
2021-07-01	Downgrade	Mizuho	Buy → Neutral
2021-04-14	Downgrade	Wedbush	Neutral → Underperform
2021-01-25	Reiterato	Piper Sandler	Overweight
2020-09-23	Iniziato	Northland Capital	Outperform
2020-09-18	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-17	Downgrade	Truist	Buy → Hold
2020-06-01	Ripresa	Oppenheimer	Perform
2020-05-01	Downgrade	Oppenheimer	Outperform → Perform
2020-04-09	Downgrade	Evercore ISI	In-line → Underperform
2020-03-05	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-01-02	Downgrade	Evercore ISI	Outperform → In-line
2019-07-29	Aggiornamento	SunTrust	Hold → Buy
2019-07-26	Downgrade	JP Morgan	Overweight → Neutral
2019-07-26	Downgrade	Wedbush	Outperform → Neutral
2019-03-20	Iniziato	SunTrust	Hold
2018-11-02	Downgrade	Wells Fargo	Outperform → Market Perform
2018-07-16	Iniziato	Evercore ISI	Outperform
2018-04-18	Reiterato	Mizuho	Buy
2018-02-23	Reiterato	Mizuho	Buy
2017-05-24	Aggiornamento	Wells Fargo	Market Perform → Outperform
2016-07-29	Reiterato	Wedbush	Outperform
2016-01-19	Iniziato	Barclays	Underweight
2015-12-02	Iniziato	Deutsche Bank	Hold

Mostra tutto

Novocure Ltd Borsa (NVCR) Ultime notizie

Nov 26, 2024

NVCR (NovoCure) Shares Outstanding (EOP) : 108.1 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Nov 25, 2024

Novocure's SWOT analysis: FDA approval boosts cancer tech stock prospects - Investing.com

Nov 25, 2024

NovoCure (NASDAQ:NVCR) Receives Buy Rating from HC Wainwright - Defense World

Nov 25, 2024

Nov 24, 2024

NVCR (NovoCure) Growth Rank : 8 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024

Connor Clark & Lunn Investment Management Ltd. Acquires 59,608 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Nov 23, 2024

Nov 22, 2024

FDA approves Novocure's new device for brain cancer treatment By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 21, 2024

Novocure secures FDA approval for add-ons to brain cancer treatment wearable - Yahoo Finance

Nov 21, 2024

Novocure’s HFE Transducer Arrays OK’ed with Optune Gio for Glioblastoma - MPO-mag

Nov 21, 2024

FDA approves Novocure's new device for brain cancer treatment - Investing.com

Nov 21, 2024

Novocure to Present Breakthrough TTFields Brain Cancer Treatment Data at SNO Meeting | NVCR Stock News - StockTitan

Nov 21, 2024

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma - Yahoo Finance

Nov 21, 2024

Nov 18, 2024

Can Novocure's PANOVA-3 Trial Of TTFields Therapy Electrify The Stock? - RTTNews

Nov 18, 2024

Nov 16, 2024

NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 16, 2024

Nov 14, 2024

NovoCure (NVCR) Shares Cross Below 200 DMA - Nasdaq

Nov 14, 2024